Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efgartigimod PH20 SC in Pemphigus (ADDRESS)
NCT04598451Phase 3Completed
- Sponsor
- argenx
- Start
- Dec 2020
- Primary completion
- Aug 2023
- Modality
- Antibody Fragments, Therapeutic Enzymes
- Countries
- 21
01
Overview
A Phase 3 trial of efgartigimod alfa + hyaluronidase-qvfc in pemphigus vulgaris (PV), pemphigus foliaceus (PF), sponsored by argenx. Started Dec 2020; status: completed.
02
Drugs
efgartigimod alfa + hyaluronidase-qvfc
03
Conditions
pemphigus vulgaris (PV)pemphigus foliaceus (PF)
Beyond the preview
Go deeper on NCT04598451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04598451.